Jarushka Naidoo
LightNews LightNews
banner
drjnaidoo.bsky.social
Jarushka Naidoo
@drjnaidoo.bsky.social
2.4K followers 260 following 39 posts
Professor of Oncology at Beaumont RCSI Cancer Centre, Dublin | Thoracic Oncologist | Immunotherapy & Immune Toxicity | Adjunct faculty Johns Hopkins University
Posts Replies Media Videos
Reposted by Jarushka Naidoo
oncodaily.bsky.social
IASLC - What Attendees Can Expect from WCLC25
@iaslc.bsky.social
@stephenvliu.bsky.social
@narjustflorezmd.bsky.social
@drjnaidoo.bsky.social

oncodaily.com/blog/wclc25-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC25 #IASLC
What Attendees Can Expect from WCLC25 - IASLC - OncoDaily
What Attendees Can Expect from WCLC25 - IASLC / cancer, IASLC, International Association for the Study of Lung Cancer, Isabelle Schmitt-Opitz, Jarushka
oncodaily.com
July 11, 2025 at 8:55 PM
Reposted by Jarushka Naidoo
oncodaily.bsky.social
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada
@drjnaidoo.bsky.social

oncodaily.com/blog/jarushk...

#ALKPositive #Cancer #LungHealthCheckIreland #OncoDaily #Oncology
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada - OncoDaily
Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada / ALK Positive, cancer, Duncan Preece, Jarushka Naidoo, Lung Health
oncodaily.com
June 22, 2025 at 5:30 PM
drjnaidoo.bsky.social
Congrats #DavidOReilly
on the PLAN trial: plasma-first liquid biopsy (LB) v tissue (TB) for NSCLC in🇮🇪 @EJCancer
- 138pts
- 3wk⬇️ time to genomic result,LB>TB
- 90% concordance
- LB half the cost (micro-cost analysis)
@oncoalert.bsky.social @cancertrialsie.bsky.social
www.ejcancer.com/article/S095...
Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study
We report a pilot clinical trial investigating the feasibility of liquid biopsy genotyping (LBG) at the time of radiological suspicion of advanced NSCLC, incorporating a micro-cost model (MCM). (PLAsm...
www.ejcancer.com
June 19, 2025 at 2:14 AM
Reposted by Jarushka Naidoo
targetingras.bsky.social
🎤 Meet @drjnaidoo.bsky.social , from Beaumont @rcsi.bsky.social  Cancer Centre (Dublin, Ireland) as a speaker at the Targeting RAS Symposium 2025.

Dr. Naidoo will give her talk during Session 5 on Day 2 at 09:25h. 

🔗 https://targetingras.com/registration/

#TargetingRAS2025 #25anniversaryCIC
June 8, 2025 at 10:34 AM
Reposted by Jarushka Naidoo
anmwongnz.bsky.social
What an inspiring video to wake up to!

🙌find strength in your team
🙌defend what is right
🙌you can do ANYTHING but not everything
🙌fight imposter syndrome - you deserve to be there

youtu.be/i6fe2EK2lh8?...

@solangepeters.bsky.social
@drjnaidoo.bsky.social

#ESMO #Women4Oncology #oncology
Diary of an oncology leader: Episode 1 – Solange Peters
YouTube video by European Society for Medical Oncology (ESMO)
youtu.be
March 12, 2025 at 9:36 AM
Reposted by Jarushka Naidoo
yvonnediaz.bsky.social
Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM
Photo of Dr Naidoo on stage Dr Naidoo presenting conclusions Compares future to various movies
March 5, 2025 at 1:00 PM
Reposted by Jarushka Naidoo
gerryhanna.bsky.social
Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC

➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy.

➡️ Continued evidence of a benefit from PCI in LS-SCLC
March 5, 2025 at 12:55 PM
Reposted by Jarushka Naidoo
oncolojo.bsky.social
With the successful role out of the TLHC programme, we now have a growing cohort of stage 1 SCLC patients. Hopefully this will become even more common, and work needed to understand optimal patient management @drjnaidoo.bsky.social #BTOG25
March 5, 2025 at 12:28 PM
Reposted by Jarushka Naidoo
drsanjaypopat.bsky.social
Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social!

@btog.bsky.social #BTOG25
carlesescriu.bsky.social Carles Escriu @carlesescriu.bsky.social · Mar 5
SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.

Translational studies to aid patient selection will now be more needed than ever.
btog.bsky.social BTOG @btog.bsky.social · Mar 5
Welcome back for the last day of #BTOG25! The first session of the day will begin at 9.00 but refreshments are available from 8am! #LCSM

Today’s Prevention and Staging session is chaired by Alan Kirk and Emma O’Dowd with Graham Warren, Richard Lee, Luigi Ventura and Helen Liddicoat speaking.
March 5, 2025 at 1:49 PM
Reposted by Jarushka Naidoo
gerryhanna.bsky.social
Fantastic over of #radiation induced pneumonitis by #ESTRO President @mguckenberger.bsky.social at #BTOG25

Updates the congress on the new #ESTRO guidelines in this area

@drjnaidoo.bsky.social @drpeedell.bsky.social
March 3, 2025 at 11:50 AM
drjnaidoo.bsky.social
Long-Term Toxicity of Immune Checkpoint Inhibitors @jama.com

Here, our stellar fellow #ChrisCronin charts a roadmap of how to quantitate the nuanced toxicities of IO from irAEs to time toxicity towards IO survivorship

#CancerCentreIre @oncoalert.bsky.social #LCSM
jamanetwork.com/journals/jam...
Long-Term Toxicity of Immune Checkpoint Inhibitors
This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...
jamanetwork.com
February 27, 2025 at 9:32 PM
drjnaidoo.bsky.social
Interesting new compound in the KRAS world, BBO-8520 @theaacr.bsky.social
- First-In-Class inhibitor of KRAS G12Ci in GTP-Bound (ON)+GDP-Bound (OFF) states
- Ph I ONKORAS-101 trial ongoing, BBO-8520+\- pembro

@oncoalert.bsky.social @kraskickers.bsky.social #LCSM

aacrjournals.org/cancerdiscov...
Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C
Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...
aacrjournals.org
February 17, 2025 at 10:33 PM
drjnaidoo.bsky.social
IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪

Registration & abstract submissions are OPEN!

Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
February 13, 2025 at 10:15 PM
drjnaidoo.bsky.social
Delighted to host @medsir.bsky.social today at #BeaumontRCSICancerCentre, exploring novel ways to develop & expand investigator initiated trials for cancer in Ireland 🇮🇪, through @cancertrialsie.bsky.social & beyond

Welcome @medsir.bsky.social

@rcsi.bsky.social #LCSM
January 30, 2025 at 2:42 PM
drjnaidoo.bsky.social
Early detection of lung cancer showcased at #BeaumontHospital GP study day today by #DanielJRyan, ahead of the start of the Beaumont-RCSI-Irish Cancer Society Lung Health Check Pilot Trial, opening this year

#EuropeLung #ERS #LungAmbition #RCSI #LCSM
January 25, 2025 at 4:05 PM
drjnaidoo.bsky.social
Are you a European clinician🇪🇺 who treats pts with IO & manages #irAEs? Join us in creating a pan-European vision for #irAE care🌍

Complete this short set of q’s on irAE care in your institution & country: vub.fra1.qualtrics.com/jfe/form/SV_...

@oncoalert.bsky.social
January 24, 2025 at 11:03 PM
drjnaidoo.bsky.social
A privilege to be part of the ESMO Women for Oncology Committee!

A snapshot of members & the important themes fostered this year: community, leadership, support 🌍

Watch this space for new creative content & events in 2025 🏆 @elinardou.bsky.social @solangepeters.bsky.social
December 31, 2024 at 2:39 PM
Reposted by Jarushka Naidoo
thanhneville.medsky.social
Dying on Xmas day is always so hard on those who are left behind. There is little we can do to make that memory ok. Here, our #PCCM fellow and #IM resident went above & beyond to serenade a dying patient on #Christmas morning. #EOLcare @3wishesprogram.bsky.social
PCCM Fellow playing guitar for dying patient. shared with permission IM resident playing guitar for dying patient. shared with permission.
December 26, 2024 at 8:30 PM
drjnaidoo.bsky.social
Can patterns of progression on IO, inform future decisions?

-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors

Prognostic, so far #LCSM

jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 26, 2024 at 8:55 PM
drjnaidoo.bsky.social
#ESMOImmuno24
Proffered paper🔥

Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social

- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal

Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
December 14, 2024 at 12:07 AM
drjnaidoo.bsky.social
#ESMOImmuno24
Proffered paper🔥

Gut microbiome in Ph III NIPPON trial (N/I/chemo v Pembro/chemo 1L) #JCOG

- Fusicatenibacter, Butyricicoccus = ⬆️ OS (esp with N+I: HR 0.56, 0.52) & ⬇️severe irAEs
- Blautia = ⬆️OS
- Prevotella species = ⬇️OS with N+I

@oncoalert.bsky.social #MedSky #OncSky #LCSM
December 14, 2024 at 12:02 AM
drjnaidoo.bsky.social
Ph 1/2 trial selinexor+docetaxel in adv KRAS+ NSCLC @theaacr.bsky.social

- selinexor is a XPO1 inhibitor with activity in KRAS+ PDX models, p53 is neg predictor of response
- 40pts, MTD 60mg weekly
- ORR 80 v 27% KRAS+/p53WT v p53+

@oncoalert.bsky.social #LCSM

aacrjournals.org/clincancerre...
Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer
Abstract. Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated thi...
aacrjournals.org
December 12, 2024 at 7:49 AM
drjnaidoo.bsky.social
Can gender & genetics impact alectinib tox? @jtoonline.bsky.social

- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox

#Medsky #Oncsky #LCSM

www.jto.org/article/S155...
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer
Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.
www.jto.org
December 9, 2024 at 8:46 PM
Reposted by Jarushka Naidoo
jackwestmd.bsky.social
Tables and Tornadoes: The Best Tools for the Job?

Tables (sometimes BIG) are among most routinely used tools to show data like baseline characteristics & AEs, while “tornado plots” are a standard figure to display AEs & sometimes other variables.

But could we do better, esp for live talks? (1/8)
December 4, 2024 at 11:14 PM
drjnaidoo.bsky.social
FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial:

- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP

www.fda.gov/drugs/resour...

#MedSky #OncSky #LcSM @oncoalert.bsky.social
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
www.fda.gov
December 5, 2024 at 7:58 AM